NPS pockets $30M, parts ways with AstraZeneca
NPS Pharmaceuticals and AstraZeneca are ending their six-year-old collaboration to develop new drugs for metabotropic glutamate receptors, or mGluRs. AstraZeneca is paying NPS $30 million for the full rights to the research. NPS says it will earmark these new funds for late-stage product development.
"This strategic move creates investment flexibility for NPS and enables us to use the monies from this deal, the previously announced Nycomed GATTEX deal and the approximately $10 million in savings over the next two years from this transaction to support the further development of our late-stage pipeline products, PREOS and GATTEX, in specialty indications," said NPS CEO Tony Coles.
- see the release on the breakup
ALSO: Just yesterday billionaire George Soros cut his investment in NPS to 1.8 percent. Report
Related Articles:
Analyst puts NPS Pharma under microscope. Report
NPS sells drug rights. Report
NPS halves workforce in restructuring. Report
NPS sells two facilities. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
